Universal Ibogaine Inc. (IBO.V)

CAD 0.02

(0.0%)

Long Term Debt Summary of Universal Ibogaine Inc.

  • Universal Ibogaine Inc.'s latest annual long term debt in 2022 was 1.73 Million CAD , up 2796.12% from previous year.
  • Universal Ibogaine Inc.'s latest quarterly long term debt in 2023 Q3 was 2.52 Million CAD , up 16.49% from previous quarter.
  • Universal Ibogaine Inc. reported annual long term debt of 60 Thousand CAD in 2021, down 0.0% from previous year.
  • Universal Ibogaine Inc. reported annual long term debt of - CAD in 2020, down 0.0% from previous year.
  • Universal Ibogaine Inc. reported quarterly long term debt of 2.16 Million CAD for 2023 Q2, up 190.01% from previous quarter.
  • Universal Ibogaine Inc. reported quarterly long term debt of 748.22 Thousand CAD for 2023 Q1, down -56.94% from previous quarter.

Annual Long Term Debt Chart of Universal Ibogaine Inc. (2022 - 2017)

Historical Annual Long Term Debt of Universal Ibogaine Inc. (2022 - 2017)

Year Long Term Debt Long Term Debt Growth
2022 1.73 Million CAD 2796.12%
2021 60 Thousand CAD 0.0%
2020 - CAD 0.0%
2019 - CAD 0.0%
2018 - CAD 0.0%
2017 - CAD 0.0%

Peer Long Term Debt Comparison of Universal Ibogaine Inc.

Name Long Term Debt Long Term Debt Difference
Arch Biopartners Inc. 703.92 Thousand CAD -146.856%
Covalon Technologies Ltd. 919.08 Thousand CAD -89.067%
Hemostemix Inc. 4.32 Million CAD 59.79%
Kane Biotech Inc. 1.3 Million CAD -33.414%
MedMira Inc. 2.95 Million CAD 41.24%
Marvel Biosciences Corp. 1 Million CAD -73.767%
NervGen Pharma Corp. 105.6 Thousand CAD -1545.461%
XORTX Therapeutics Inc. - CAD -Infinity%